Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

9.14
-0.5600-5.77%
Volume:309.22K
Turnover:2.84M
Market Cap:926.38M
PE:-8.92
High:9.48
Open:9.48
Low:8.94
Close:9.70
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Feb

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

Zacks
·
13 Feb

New Strong Buy Stocks for February 13th

Zacks
·
13 Feb

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

GlobeNewswire
·
11 Feb

Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)

TIPRANKS
·
11 Feb

Tara Bancroft’s Buy Rating: Ojemda’s Promising Growth and Strong Financial Prospects

TIPRANKS
·
29 Jan

Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

Insider Monkey
·
23 Jan

Strategic Positioning and Growth Potential of Day One Biopharmaceuticals: A Buy Rating Driven by Ojemda’s Market Penetration

TIPRANKS
·
16 Jan

Day One Biopharm Price Target Maintained With a $33.00/Share by Needham

Dow Jones
·
14 Jan

Optimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy Rating

TIPRANKS
·
13 Jan

Press Release: Day One Reports Preliminary 2024 OJEMDA(TM) Net Product Revenue and Highlights 2025 Corporate Priorities

Dow Jones
·
13 Jan

Day One Biopharm Is Maintained at Buy by B of A Securities

Dow Jones
·
08 Jan

BofA Securities Adjusts Price Target on Day One Biopharmaceuticals to $25 From $28, Maintains Buy Rating

MT Newswires Live
·
07 Jan

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Zacks
·
27 Dec 2024

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.
·
24 Dec 2024

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk

TIPRANKS
·
17 Dec 2024